Background: Combination of dyslipidemic phenotypes, including elevated plasma levels of low-density lipoprotein cholesterol (LDL-C), elevated plasma triglycerides (TG), and decreased low-density lipoprotein cholesterol (HDL-C) concentrations, is important because of the association of individual phenotypes with increased risk of cardiovascular disease (CVD). We investigated the prevalence of combined dyslipidemias and their effects on CVD risk in an Iranian large population.
Method: A total of 9847 individuals were recruited as part of the Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study. Anthropometric parameters and biochemical indices were measured in all of the subjects. Different types of combined dyslipidemias including high TG + low HDL-C, high TG + low HDL-C + high LDL-C, low HDL-C + high LDL-C, high TG + high LDL-C, and finally high TG + high LDL-C + low HDL-C were considered. Ten-year CVD risk was calculated
| INTRODUC TI ON
Dyslipidemia is a modifiable cardiovascular (CV) risk factor that is manifested as elevated plasma low-density concentrations of low-density lipoprotein cholesterol (LDL-C) or triglycerides (TG), or low plasma high-density lipoprotein cholesterol (HDL-C) concentrations. 1 The prevalence of dyslipidemia has an increasing trend in many countries including those located in the Middle East region. 2 The prevalence of both low HDL-C and high LDL-C has been reported to be increased in women. In Iran, the prevalence of hypercholesterolemia is greater in women (38.9% in men and 41.8% in women) but hypertriglyceridemia is more common in men (47% in men and 42.5% in women). 3 The prevalence of dyslipidemia has increased in adolescents from Eastern Iran, in whom there at least one lipid abnormality is present in 34.3% of individuals. 4 Combined dyslipidemia is typically considered as a mixed phenotype of elevated plasma LDL-C and TG levels, usually accompanied by decreased HDL-C concentrations and preponderance of smalldense LDL particles. 5 It has been indicated that combined dyslipidemia is highly prevalent in obese individuals 6 in whom there is a 30%-60% prevalence of hypertriglyceridemia, usually associated with decreased HDL-C levels. 7, 8 Cardiovascular disease (CVD) is one of the most important causes of death globally, and its incidence is rising because the risk factors that lead to the CVD such as hypertension, diabetes, obesity, and dyslipidemia are increasing in prevalence. Atherosclerosis is the underlying cause of CVD 9 and dyslipidemia is a well-documented contributor to this process. As elevated plasma levels of LDL-C and TG, and reduced plasma HDL-C are individually known to promote atherogenesis, accumulation of these phenotypes in combined dyslipidemias introduces a greater CVD risk. [10] [11] [12] Therefore, it will be crucial to obtain population data on the prevalence of combined dyslipidemias and the association of each dyslipidemia phenotype with CVD risk. We aimed to fulfill this task using a large Iranian cohort database.
using the QRISK2 risk algorithm and adjustments were made as suggested by the Joint British Societies' (JBS2). Logistic regression analyses were performed to determine the association between different combined dyslipidemias and categorical
QRISK.
Results: A total of 3952 males and 5895 females were included in this current study. TA B L E 2 Anthropometric and biochemical characteristics of subjects with dyslipidemia (n:9844) 
Pvalue

| Anthropometric and biochemical measurements
Anthropometric parameters, including height, body weight, Body mass index (BMI) and waist and hip circumference (WC and HC)
were measured in all the subjected as previously described, 13 while systolic and diastolic blood pressures were measured by sphygmomanometers. 13, 14 A fasted lipid profile, including total cholesterol (TC), HDL-C, LDL-C, TG and fasting blood glucose (FBG) and serum C-reactive protein (CRP), and uric acid were measured using standard procedure as described previously 15 High values for the lipid components and combined dyslipidemia categorizes are shown in Table 1 .
| QRISK
QRISK is estimation of 10-year risk of CVD and it was calculated and the adjustments made as suggested by the Joint British Societies'
(JBS2) paper and the JBS Cardiovascular Risk Assessor (patient.info/ doctor/cardiovascular-risk-calculator). 16 Using QRISK, we calculated the 10-year risk of CVD for every patient in MASHAD Study cohort.
| Statistical analysis
Differences in variables (aside from age) among dyslipidemia determined using ANCOVA analyses with age included as model covariates.
Data were analyzed using SPSS-18 software (SPSS Inc., IL, USA). 
| RE SULTS
| Demographic characteristics and the presence of dyslipidemia in males and females
Clinical and demographic characteristics of participants are presented in Table 2 . A total of 3952 (40.1%) males and 5892 (59.9%) females were recruited into the current study (Table 2) . Among total subjects, 8210 (83.4%) had one form of dyslipidemia (hypertriglyceridemia and low level of HDL-C, hypertriglyceridemia and low level of HDL-C and increased LDL-C, low level of HDL-C and increased LDL-C, hypertriglyceridemia and increased LDL-C, hypertriglyceridemia or low level of HDL-C or increased LDL-C), and 1637 (16.6%) subjects were not dyslipidemic.
The results showed that the levels of BMI, WC, HC, SBP, DBP, FBG, hs-CRP, Uric acid were significantly increased in the dyslipidemic groups and HDL was significantly decrease in the dyslipidemic groups ( Table 2 ).
| Prevalence of dyslipidemia
The mean age was 48.88 ± 7.9 and 47.02 ± 8.54 years for dyslipidemia and control groups, respectively. Among the 8210 subjects who were dyslipidemic, 3100 (37.77%) were male and 5110 (62.23%) F I G U R E 1 Phenotype of combine dyslipidemia*, *P < .05
were female. According to sex females and males who had dyslipidemia was 86.8% and 78.5%, respectively ( Table 1 ). The proportion of females who had dyslipidemia according to dyslipidemia subgroups was significantly higher than males (P < .001, Table 2 , Figure 1 ).
There were 1695 subjects with increased TG and low HDL-C level, 895 with increased TG and low HDL-C and increased LDL-C levels, 1069 with low HDL-C and increased LDL-C levels, 384 with increased TG and LDL-C levels, and finally 4167 subjects with only one of these dyslipidemia (increased TG or increased LDL-C or decreased HDL-C levels).
We investigated the prevalence of dyslipidemia in subjects with metabolic syndrome, CVD, diabetes and smoking status ( Table 3 ).
The results showed that the frequency of dyslipidemia was 98%, 87.1%, 90% and 85.7% in subjects with metabolic syndrome, CVD, diabetes and smoked, respectively.
| 10-year CAD risk
Our results showed that around 15.7% of the study population were at 10 years CVD risk (high ≥20) and it was higher in men than women (P < .001). The results demonstrated that 10-year CVD risk was higher in subjects with TG↑ and HDL-C↓ and LDL-C↑ group compared with other dyslipidemic groups (Figure 2) . A logistic regression model investigates the most important lipid determinant of the 10-year CVD risk. After adjustment for gender and diabetes, TG↑ and HDL↓ and LDL↑ group was the strongest predictor of the 10-year CVD risk (Table 4) .
| D ISCUSS I ON
The results of current study showed that prevalence of dyslipidemia was 83.4% among Iranian adults. Moreover, the frequency of dyslipidemia was 98%, 87.1% and 90% in subjects with metabolic syndrome, CVD, and diabetes, respectively. It has been demonstrated TA B L E 3 Status of disease and dyslipidemia F I G U R E 2 10 years cardiovascular disease (CVD) risk according phenotype of combined and noncombined dyslipidemia*, *P < .05
Pvalue
that obesity 17 and diabetes 18 are common secondary causes of dyslipidemia. 17, 18 Previous studies showed that overweight and obesity increase the risk of CVD. Central obesity may be associated with the constellation of cardiovascular and metabolic risk factors including hypertriglyceridemia, low HDL-C levels, increased blood pressure and FBG known as the metabolic syndrome. 19 In the current study, we compared the risk of CVD in the people with combined dyslipidemia and healthy subjects. The results
showed that 10 -year CVD risk was higher in men than women. A large cohort study in UK, showed that the 10-year risk of CVD was 32% in men and 10% in women. 16 This result is consistent with the current study observation.
It has been shown that atherogenic dyslipidemia, the combination of increased triglycerides and low HDL-C levels, is associated with an increased risk of silent myocardial ischemia and silent CAD in patients with type 2 diabetes mellitus and LDL-C levels <3.35 mmol/L. Specific management of atherogenic dyslipidemia can help reducing the high residual burden of CVD. 20 Our results
showed that 24.3% of subjects with atherogenic dyslipidemia were current smokers. Moreover, 25.8% patients with T2DM were atherogenic dyslipidemia. Previous studies demonstrated that the most common risk factors of atherosclerotic heart disease or stroke are dyslipidemia and abnormalities in some coagulation and hemostatic factors, increased blood pressure and smoking. 21 The results of current research showed that individuals with TG↑ plus HDL↓ plus LDL↑ had the greatest QRISK compared with other combined dyslipidemia groups. This finding is in consistent with other previous cohort reports. The results of NHANES survey showed that the TC, LDL-C and glucose levels remain unchanged over multiple cohorts of US children and adolescents, but there has been an increase in TG levels and a decrease in HDL-C concentrations. 22 Impaired triglyceride metabolism can promote atherogenesis. Patients with HTG have decreased HDL-C levels.
Moreover, disturbed fatty acid metabolism is reported in these patients. 23 Atherogenic dyslipidemia is reported in more than half of subjects with NAFLD. 24 It has been shown that dyslipidemia is strongly associated with related cardiometabolic risk factors.
Visceral adiposity in subjects with underlying genetic susceptibility can initiate a cascade of pathophysiologic responses which can result in combined dyslipidemia, insulin resistance/T2DM and NAFLD. TA B L E 4 Unadjusted and multivariateadjusted prevalence ratios of the 10 years risk of cardiovascular disease (CVD) (<20(low to moderate) and ≥20 (high)) with different criteria of dyslipidemia
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| CON CLUS ION
